Jaguar Health, Inc.
No enriched coverage for $JAGX in the last 7 days.
No SEC Form 4 filings for $JAGX in the last 30 days.
See all $JAGX insider activity →Jaguar Health (JAGX) reported that crofelemer reduced parenteral support by 15% in an infant with GUCY2C-related IF. The company plans to file an NDA for crofelemer in MVID by mid-2027, following the completion of a pivotal trial's enrollment.
Jaguar Health (NASDAQ:JAGX) announced a special stock dividend payable on October 15, 2026, with an ex-dividend date of October 16, 2026. The dividend aims to protect shareholders from dilution as the company explores strategic alternatives. Jaguar expects to file an NDA for crofelemer to treat microvillus inclusion disease in mid-2027, according to CEO Lisa Conte.
Jaguar Health's unit, Napo Pharmaceuticals, reported preliminary results from a study of crofelemer in Type 1 short bowel syndrome patients. The study showed mixed results on ostomy volume reduction, with some patients experiencing decreased output and others increased. No significant adverse events were noted. Napo plans to file a New Drug Application for microvillus inclusion disease in mid-2027 and expects Phase 2 trial results in early 2027.
Recent JAGX coverage spans financial news, corporate actions and market movers.
Positive early‑stage data and a clear regulatory path suggest upside for the stock.
The dividend aims to protect against dilution and may attract short‑term buying, but due‑bill complexities could cause trading friction.
Early-phase data suggests crofelemer may reduce ostomy output, supporting a potential NDA filing in 2027.
Positive early‑stage data may lift sentiment and attract speculative buying.
The stock surged on the announcement; short‑term pressure may develop as the rally fades.
AlphAI scores every news story that mentions JAGX with an AI model for sentiment and relevance, and aggregates insider trades from Jaguar Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jaguar Health (JAGX) reported that crofelemer reduced parenteral support by 15% in an infant with GUCY2C-related IF. The company plans to file an NDA for crofelemer in MVID by mid-2027, following the completion of a pivotal trial's enrollment.
2 min readJaguar Health (NASDAQ:JAGX) announced a special stock dividend payable on October 15, 2026, with an ex-dividend date of October 16, 2026. The dividend aims to protect shareholders from dilution as the company explores strategic alternatives. Jaguar expects to file an NDA for crofelemer to treat microvillus inclusion disease in mid-2027, according to CEO Lisa Conte.
1 min readJaguar Health's unit, Napo Pharmaceuticals, reported preliminary results from a study of crofelemer in Type 1 short bowel syndrome patients. The study showed mixed results on ostomy volume reduction, with some patients experiencing decreased output and others increased. No significant adverse events were noted. Napo plans to file a New Drug Application for microvillus inclusion disease in mid-2027 and expects Phase 2 trial results in early 2027.
2 min readJaguar Health (JAGX) reported positive preliminary results from an ongoing open-label pilot study of oral crofelemer in adult T1SBS-IF, showing reduced ostomy output in some patients with no significant adverse events. A Phase 2 trial is ongoing, with results expected in early H2 2027, according to the company.
1 min readJaguar Health (JAGX) shares rose after its subsidiary, Napo Pharmaceuticals, announced a sponsorship for an intestinal failure discussion at an Abu Dhabi conference. Napo is developing crofelemer for rare intestinal failure diseases, with a New Drug Application filing targeted for mid-2027. Earlier data showed reductions in parenteral support requirements for patients. JAGX is up 29.81% at $6.14.
1 min readJaguar Health (JAGX) targets mid-2027 NDA filing for crofelemer in treating microvillus inclusion disease. Napo Pharmaceuticals, its subsidiary, is advancing the drug's development for intestinal failure. Recent data showed reductions in parenteral support needs in pediatric patients. The company will sponsor a panel at a pediatric gastroenterology conference in Abu Dhabi on October 30.
2 min readJaguar Health Inc. (JAGX) stock rose 33.62% on news of drug-development progress. The company's rare-disease pipeline, including crofelemer for MVID and SBS-IF, is advancing with a pivotal trial and potential NDA filing in mid-2027. JAGX has high volatility, negative cash flow, and relies on financing. Revenue is $11.5M annually with an 82% gross margin. The company is exploring strategic alternatives and declared a special stock dividend.
3 min readJaguar Health (NASDAQ:JAGX) shares surged 34.67% to $6.37 in after-hours trading. The company declared a special dividend of Series R Convertible Preferred Stock, convertible into common shares. It also extended debt payments to 2027. JAGX has a market cap of $9.20 million and an RSI of 45.39, trading near its yearly low.
1 min readJaguar Health amended agreements with Uptown and Streeterville Capital to defer royalty payments to 2027, with a $750,000 monthly minimum. It extended a $6.22M note's maturity to 2027. The company also gained consent from Series P investors to issue a preferred dividend, adding a repurchase covenant. These moves aim to improve liquidity.
1 min readJaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Jaguar Health Announces a Special Stock Dividend Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / October 2, 2026 / Jaguar Health, Inc . ( NASDAQ: JAGX ) (“Jaguar” or
1 min read
